News: SUD Suda Ltd says Artimist accepted for review marketing authorisation, page-18

Imho I think we may have missed the *big* boat on Artimist. There's still a market for treating (not curing) children and those who cannot tolerate the standard treatments, or for those who are a distance from a treatment centre and don't have the storage/refrigeration (the standard treatments have specific needs). But imho the larger market is potentially gone because the vaccination trials in Germany and Australia have gone so well (news on those trials Feb and Mar this year). In a nutshell, they've now trialled human subjects successfully - the Aussies for a vaccine against multiple strains and the Germans for a vaccine against a single strain. There's only so much funding for these projects, where do you think most of the pharma $$ will be focussed, on a cure (vaccination) or on a treatment to buy time and limit discomfort for a much smaller % of malaria sufferers? Ethically it should be both. Reality is a funny thing when it comes to budgets.... Sud better find a sale for Artimist asap to max the value as there is still a window until the vacc reaches it's audience. I agree with Dan1, why has it taken Sud so long to get this product that was so well advanced before to the TGA? You don't need 3+ years to do that. It's a fair comment that there aren't enough people now, but I question a strategy that doesn't/didn't budget the right resources to the right tasks to protect/max a market. My guess is that the "distractions" as people here call them have been a bit... well... distracting and mgt haven't implemented (or had the cash to implement) a strong business plan effectively and max a great product (Artimist). Just my opinion based on comments here that throw up reasons why Sud couldn't have performed, "there's only two of them", papers take time to write, other partners (one of them sueing us now) didn't perform their jobs properly, etc. Fek it will be frustrating if that costs them a podium spot....